Home » Newsletters » BioWorld Science

BioWorld Science

June 22, 2007

View Archived Issues

Preclinical and clinical studies on Rebif(R) new formulation

Recent patents disclose new agents for depression, anxiety, psychosis and sleep disorders

Novel agents for treating endocrine-related disorders disclosed in recent patent literature

New therapeutic agents for respiratory and allergic disorders disclosed in recent patents

Novartis invests in Adenosine Therapeutics

Health Canada approves once-daily tramadol

Merck Serono and Ambrx collaborate on growth hormone products

OSI Pharmaceuticals begins phase I trials of OSI-906 for tumors

Recent Janssen and Pfizer patents describe novel analgesic agents

Rylomine significantly reduces postsurgical orthopedic pain

Interim findings for AVN-944 in hematologic malignancies

Kaken and Sunstar sign agreement for bFGF dental product development

NOP receptor antagonist improves parkinsonian-related motor dysfunction

New preclinical data on short-acting sedative CNS-7056

Liraglutide provides better glucose control than insulin glargine in phase III study

Phosphagenics delivery technology shows promise in dermatological fields

EULAR 2007: Studies of certolizumab pegol in rheumatoid arthritis

ARRY-797 meets endpoints in phase I study

ZymoGenetics and Bayer collaborate in global development of rThrombin

FDA agrees on SPA for OxyADF phase III trial

Bayer Schering Pharma to license imaging agent from Avid

DeveloGen grants worldwide exclusive license to Teva for protein kinase B

Resverlogix and Sun Health Research Institute collaborate for treatment of AD

Genzyme seeks FDA approval of Synvisc-One

Inulin polysulfate in vitro studies indicate potential to prevent osteoarthritis progression

Approvable letter for Risperdal sNDAs

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...